Evidence map›Paper›PMID 27023536›Full record

ArticleInternational journal of molecular sciences2016

Liver Fibrosis in HCV Monoinfected and HIV/HCV Coinfected Patients: Dysregulation of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors TIMPs and Effect of HCV Protease Inhibitors.

Tiziana Latronico, Claudia Mascia, Ilaria Pati, Paola Zuccala, Fabio Mengoni, Raffaella Marocco, Tiziana Tieghi, Valeria Belvisi, Miriam Lichtner, Vincenzo Vullo and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 47 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Scar-Degrading Endothelial Cells as a Treatment for Advanced Liver Fibrosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. (-)-Catechin-7-Cells · 2019
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Tiziana LatronicoDepartment of Biosciences, Biotechnologies and Biopharmaceutics, Aldo Moro University, Bari 70126, Italy. tiziana.latronico@uniba.it.
Claudia MasciaDepartment of Public Health and Infectious Diseases, Sapienza University, Rome 00185, Italy. claumascia@tiscali.it.
Ilaria PatiDepartment of Biosciences, Biotechnologies and Biopharmaceutics, Aldo Moro University, Bari 70126, Italy. ilaria.pati@hotmail.it.
Paola ZuccalaDepartment of Public Health and Infectious Diseases, Sapienza University, Rome 00185, Italy. paola.zuccala@libero.it.
Fabio MengoniDepartment of Public Health and Infectious Diseases, Sapienza University, Rome 00185, Italy. fabio.mengoni@uniroma1.it.
Raffaella MaroccoInfectious Diseases Unit, Sapienza University, Polo Pontino, Latina 04100, Italy. raffa.marocco@libero.it.
Tiziana TieghiDepartment of Public Health and Infectious Diseases, Sapienza University, Rome 00185, Italy. tizianatieghi@libero.it.
Valeria BelvisiDepartment of Public Health and Infectious Diseases, Sapienza University, Rome 00185, Italy. valeria.belvisi@gmail.com.
Miriam LichtnerDepartment of Public Health and Infectious Diseases, Sapienza University, Rome 00185, Italy. miriam.lichtner@uniroma1.it.
Vincenzo VulloDepartment of Public Health and Infectious Diseases, Sapienza University, Rome 00185, Italy. vincenzo.vullo@uniroma1.it.
Claudio Maria MastroianniDepartment of Public Health and Infectious Diseases, Sapienza University, Rome 00185, Italy. claudio.mastroianni@uniroma1.it.
Grazia Maria LiuzziDepartment of Biosciences, Biotechnologies and Biopharmaceutics, Aldo Moro University, Bari 70126, Italy. graziamaria.liuzzi@uniba.it.
Sapienza University of Rome · ITUniversity of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An imbalance between matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) may contribute to liver fibrosis in patients with hepatitis C (HCV) infection. We measured the circulating levels of different MMPs and TIMPs in HCV monoinfected and HIV/HCV coinfected patients and evaluated the potential for anti-HCV therapy to modulate MMP and TIMP levels in HCV subjects. We analyzed 83 plasma samples from 16 HCV monoinfected patients undergoing dual or triple anti-HCV therapy, 15 HIV/HCV coinfected patients with undetectable HIV load, and 10 healthy donors (HD). Levels of MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, MMP-10, TIMP-1, and TIMP-2 were measured by a SearchLight Multiplex Immunoassay Kit. MMP-2 and MMP-9 were the highest expressed MMPs among all the analyzed samples and their levels significantly increased in HCV monoinfected and HIV/HCV coinfected subjects compared to HD. TIMP-1 levels were significantly higher in HCV and HIV/HCV subjects compared to HD and were correlated with liver stiffness. These findings raise the possibility of using circulating TIMP-1 as a non-invasive marker of liver fibrosis in HCV infection. A longitudinal study demonstrated that MMP-9 levels significantly decreased (40% reduction from baseline) in patients receiving dual as well as triple direct-acting antivirals (DAA) anti-HCV therapy, which had no effect on MMP-2, TIMP-1, and TIMP-2. As the dysregulation of MMP-2 and MMP-9 may reflect inflammatory processes in the liver, the decrease of MMP-9 following HCV protease inhibitor treatment suggests a positive effect on the reduction of liver inflammation.

Indexed as

AdultAgedAntiviral AgentsFemaleHepatitis CHIV InfectionsHumansImmunoassayLiver CirrhosisLongitudinal StudiesMaleMatrix MetalloproteinasesMiddle AgedProtease InhibitorsTissue Inhibitor of MetalloproteinasesAntiviral AgentsMatrix MetalloproteinasesProtease InhibitorsTissue Inhibitor of Metalloproteinasesanti-HCV therapyHIV/HCV coinfectionliver fibrosismatrix metalloproteinasestissue inhibitors of metalloproteinases

Identifiers

PMID27023536
PMCPMC4848911
OpenAlexW2312083399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.